CD274 and non-small cell lung carcinoma: The Antonia trial on NSCLC gave the first hints of the dynamic modulation of the ICM PD-1/PD-L1-axis, and also identified a significant positive effect when radiotherapy was applied to the immunotherapeutic agent (Durvalumab®®) within a short time frame (<14 days vs. >14 days) [29].